創薬におけるAI市場は、予測期間中に29.83％という大幅なCAGRを記録すると予想されます。 創薬におけるシミュレートされたインテリジェンスの受容性の高まり、創薬における人工知能の重要な取り組みの増加、およびAIを活用した新規創薬企業の増加が、ビジネスセクターの発展を推進しています。
創薬におけるシミュレートされたインテリジェンスの受け入れは、製薬企業やバイオテクノロジー企業を含む業界で高まっています。これは基本的に、人工知能が薬物粒子の発見に進歩した利点を提供し、創薬プロセスを加速する方法によるものです。さらに、人工知能は、医薬品の設計、最適化、合成に取り組むための重要な洞察を提供します。創薬における人工知能の受容性が高まっている要因はいくつかあります。絶対的で最も顕著なものは、進行中の疾患の発生率の増加と、病気への対処と治療に対処する新しい方法による正確な医療です。さらに、一部の市場参加者は医薬品ポートフォリオの精度を高めており、このサイクルは人工知能の進歩の受容性の高まりを示しています。
目次
TABLE OF CONTENTS
1 EXECUTIVE SUMMARY
1.1 OVERVIEW
1.1.1 MARKET SYNOPSIS
2 MARKET INTRODUCTION
2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 MARKET STRUCTURE
2.5 LIST OF ASSUMPTIONS
3 RESEARCH METHODOLOGY
3.1 OVERVIEW
3.2 DATA MINING
3.3 SECONDARY RESEARCH
3.4 PRIMARY RESEARCH
3.4.1 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS
3.4.2 BREAKDOWN OF PRIMARY RESPONDENTS
3.5 FORECASTING TECHNIQUES
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
3.6.1 BOTTOM-UP APPROACH
3.6.2 TOP-DOWN APPROACH
3.7 DATA TRIANGULATION
3.8 VALIDATION
4 MARKET DYNAMICS
4.1 OVERVIEW
4.2 DRIVERS
4.2.1 INCREASING ADOPTION OF AI IN DRUG DISCOVERY
4.2.2 RISING STRATEGIC INITIATIVES FOR AI IN DRUG DISCOVERY
4.2.3 INCREASING NUMBER OF AI-POWERED DRUG DISCOVERY START-UPS
4.3 RESTRAINTS
4.3.1 SHORTAGE OF AI WORKFORCE
4.4 OPPORTUNITIES
4.4.1 EMERGING MARKETS
5 MARKET FACTOR ANALYSIS
5.1 VALUE CHAIN ANALYSIS
5.1.1 R&D
5.1.2 MANUFACTURING
5.1.3 DISTRIBUTION & SALES
5.1.4 POST-SALES MONITORING
5.2 PORTER'S FIVE FORCES MODEL
5.2.1 THREAT OF NEW ENTRANTS
5.2.2 BARGAINING POWER OF SUPPLIERS
5.2.3 THREAT OF SUBSTITUTES
5.2.4 BARGAINING POWER OF BUYERS
5.2.5 INTENSITY OF RIVALRY
5.3 IMPACT OF COVID-19 ON THE GLOBAL AI IN DRUG DISCOVERY
5.3.1 IMPACT ON SUPPLY CHAIN
5.3.2 IMPACT ON SERVICE DEMAND
5.3.3 IMPACT ON MARKET PLAYERS
6 GLOBAL AI IN DRUG DISCOVERY MARKET, BY PRODUCT AND SERVICE
6.1 OVERVIEW
6.2 SOFTWARE
6.3 SERVICES
7 GLOBAL AI IN DRUG DISCOVERY MARKET, BY MOLECULE TYPE
7.1 OVERVIEW
7.2 LARGE MOLECULE
7.3 SMALL MOLECULE
8 GLOBAL AI IN DRUG DISCOVERY MARKET, BY TECHNOLOGY
8.1 OVERVIEW
8.2 MACHINE LEARNING
8.3 DEEP LEARNING
8.4 OTHERS
9 GLOBAL AI IN DRUG DISCOVERY MARKET, BY INDICATION
9.1 OVERVIEW
9.2 IMMUNO-ONCOLOGY
9.3 NEURODEGENERATIVE DISEASES
9.4 CARDIOVASCULAR DISEASES
9.5 METABOLIC DISEASES
9.6 OTHERS
10 GLOBAL AI IN DRUG DISCOVERY MARKET, BY APPLICATION
10.1 OVERVIEW
10.2 TARGET IDENTIFICATION
10.3 CANDIDATE SCREENING
10.4 DE NOVO DRUG DESIGNING
10.5 DRUG OPTIMIZATION AND REPURPOSING
10.6 PRECLINICAL TESTING
11 GLOBAL AI IN DRUG DISCOVERY MARKET, BY REGION
11.1 OVERVIEW
11.2 NORTH AMERICA
11.2.1 US
11.2.2 CANADA
11.3 EUROPE
11.3.1 GERMANY
11.3.2 FRANCE
11.3.3 UK
11.3.4 ITALY
11.3.5 SPAIN
11.3.6 REST OF EUROPE
11.4 ASIA-PACIFIC
11.4.1 CHINA
11.4.2 JAPAN
11.4.3 INDIA
11.4.4 AUSTRALIA
11.4.5 SOUTH KOREA
11.4.6 REST OF ASIA-PACIFIC
11.5 REST OF THE WORLD
11.5.1 MIDDLE EAST
11.5.2 AFRICA
11.5.3 LATIN AMERICA
12 COMPETITIVE LANDSCAPE
12.1 OVERVIEW
12.2 COMPETITIVE BENCHMARKING
12.3 MAJOR GROWTH STRATEGY IN THE GLOBAL AI IN DRUG DISCOVERY MARKET
12.4 THE LEADING PLAYER IN TERMS OF THE NUMBER OF DEVELOPMENTS IN THE GLOBAL AI IN DRUG DISCOVERY MARKET
12.5 KEY DEVELOPMENT ANALYSIS
12.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
12.6.1 SERVICE/COMPANY LAUNCH
12.6.2 MERGER/ACQUISITION
12.6.3 PARTNERSHIP/COLLABORATION/AGREEMENT
13 COMPANY PROFILES
13.1 IBM
13.1.1 COMPANY OVERVIEW
13.1.2 FINANCIAL OVERVIEW
13.1.3 SOFTWARE/SERVICES OFFERED
13.1.4 KEY DEVELOPMENTS
13.1.5 SWOT ANALYSIS
13.1.6 KEY STRATEGIES
13.2 ALPHABET INC.
13.2.1 COMPANY OVERVIEW
13.2.2 FINANCIAL OVERVIEW
13.2.3 SOFTWARE/SERVICES OFFERED
13.2.4 KEY DEVELOPMENTS
13.2.5 SWOT ANALYSIS
13.2.6 KEY STRATEGIES
13.3 ATOMWISE INC.
13.3.1 COMPANY OVERVIEW
13.3.2 FINANCIAL OVERVIEW
13.3.3 SOFTWARE/SERVICES OFFERED
13.3.4 KEY DEVELOPMENTS
13.3.5 SWOT ANALYSIS
13.3.6 KEY STRATEGIES
13.4 DEEP GENOMICS
13.4.1 COMPANY OVERVIEW
13.4.2 FINANCIAL OVERVIEW
13.4.3 SOFTWARE/SERVICES OFFERED
13.4.4 KEY DEVELOPMENTS
13.4.5 KEY STRATEGIES
13.5 CLOUD PHARMACEUTICALS, INC.
13.5.1 COMPANY OVERVIEW
13.5.2 FINANCIAL OVERVIEW
13.5.3 SOFTWARE/SERVICES OFFERED
13.5.4 KEY DEVELOPMENTS
13.5.5 KEY STRATEGIES
13.6 MICROSOFT CORPORATION
13.6.1 COMPANY OVERVIEW
13.6.2 FINANCIAL OVERVIEW
13.6.3 SERVICES OFFERED
13.6.4 KEY DEVELOPMENTS
13.6.5 SWOT ANALYSIS
13.6.6 KEY STRATEGIES
13.7 INSILICO MEDICINE
13.7.1 COMPANY OVERVIEW
13.7.2 FINANCIAL OVERVIEW
13.7.3 SERVICES OFFERED
13.7.4 KEY DEVELOPMENTS
13.7.5 KEY STRATEGIES
13.8 CYCLICA
13.8.1 COMPANY OVERVIEW
13.8.2 FINANCIAL OVERVIEW
13.8.3 SERVICES OFFERED
13.8.4 KEY DEVELOPMENTS
13.8.5 KEY STRATEGIES
13.9 BENEVOLENTAI
13.9.1 COMPANY OVERVIEW
13.9.2 FINANCIAL OVERVIEW
13.9.3 SERVICES OFFERED
13.9.4 KEY DEVELOPMENTS
13.9.5 SWOT ANALYSIS
13.9.6 KEY STRATEGIES
13.10 EXSCIENTIA
13.10.1 COMPANY OVERVIEW
13.10.2 FINANCIAL OVERVIEW
13.10.3 SOFTWARES OFFERED
13.10.4 KEY DEVELOPMENTS
13.10.5 KEY STRATEGIES
14 APPENDIX
14.1 REFERENCES
14.2 RELATED REPORTS
